---
title: "Moleculin poster acceptance at ASCO shows pooled Annamycin cardiac safety across 90 patients"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287399847.md"
description: "Moleculin announced the acceptance of a poster at ASCO 2026, presenting pooled cardiac safety data for Annamycin, indicating no drug-induced cardiotoxicity. The independent review involved 90 patients, with a median Annamycin dose of 660 mg/m2. No significant changes in LVEF were observed, and serial ECGs and biomarkers supported the findings, reinforcing the rationale for the MIRACLE trial."
datetime: "2026-05-22T20:03:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287399847.md)
  - [en](https://longbridge.com/en/news/287399847.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287399847.md)
---

# Moleculin poster acceptance at ASCO shows pooled Annamycin cardiac safety across 90 patients

**Moleculin announced an ASCO poster acceptance presenting pooled cardiac safety data for Annamycin showing no evidence of drug-induced cardiotoxicity.**

**Key Highlights:**

-   Abstract on pooled cardiac safety for Annamycin accepted for poster presentation at ASCO 2026 (May 30, Poster Board #8).
-   Independent cardiac review covered 90 patients from five completed trials; 78 had source-verified LVEF assessments.
-   Median cumulative Annamycin dose 660 mg/m2 (95% CI 645–690); most doses exceeded conventional anthracycline lifetime limits.
-   No significant change in LVEF from baseline to final (mean diff -0.12%; 95% CI -1.34 to 1.09; p=0.84) and no dose or age correlation with LVEF change.
-   Serial ECGs, biomarkers, cardiac AEs and global longitudinal strain showed no evidence of drug-induced cardiotoxicity, supporting MIRACLE trial rationale.

Original SEC Filing: Moleculin Biotech, Inc. \[ MBRX \] - 8-K - May. 22, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)

## Related News & Research

- [Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment | MBRX Stock News](https://longbridge.com/en/news/288725004.md)
- [Moleculin highlights favorable cardiac safety data for Annamycin](https://longbridge.com/en/news/286120143.md)
- [GRAIL Presents Positive PATHFINDER 2 Results Of Galleri MCED Test At ASCO 2026](https://longbridge.com/en/news/288228856.md)
- [Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting | MBRX Stock News](https://longbridge.com/en/news/283502009.md)
- [Moleculin Nears First Unblinding in Pivotal MIRACLE Trial](https://longbridge.com/en/news/286263542.md)